您的购物车当前为空
别名 迪帕西单抗, PR1283233, PR 1283233, ABT-165, ABT165
Dilpacimab (ABT165) 是一种强效的双可变区免疫球蛋白,可同时靶向 delta-like ligand 4 (DLL4) 与血管内皮生长因子(VEGF)信号通路。由于其对肿瘤血管生成和 Notch 信号的双重靶向,Dilpacimab 在癌症研究中具有显著潜力。

为众多的药物研发团队赋能,
让新药发现更简单!
Dilpacimab (ABT165) 是一种强效的双可变区免疫球蛋白,可同时靶向 delta-like ligand 4 (DLL4) 与血管内皮生长因子(VEGF)信号通路。由于其对肿瘤血管生成和 Notch 信号的双重靶向,Dilpacimab 在癌症研究中具有显著潜力。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 4,970 | In Stock | |
| 5 mg | ¥ 9,870 | In Stock | |
| 10 mg | ¥ 13,700 | In Stock | |
| 25 mg | ¥ 19,800 | In Stock | |
| 50 mg | ¥ 27,600 | In Stock |
Dilpacimab 相关产品
| 产品描述 | Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling. |
| 别名 | 迪帕西单抗, PR1283233, PR 1283233, ABT-165, ABT165 |
| CAS No. | 1791420-09-1 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
评论内容